BibTex RIS Cite

-

Year 2000, Volume: 1 Issue: 3, 39 - 46, 01.12.2000

Abstract

-

References

  • 1 Braun-Falco O, Plewig G, Wolff HH, Winkelmann RK. Dermatology. 4 ed. Berlin: Springer-Verlag, 1991:772-4.
  • 2 Dawber RPR, Ebling FJG, Wojnarowska FT. Disorders of hair. In: Champion RH, Burton JL, Ebling FJG (eds). Textbook of dermatology, 5 ed. Oxford: Blackwell Scientific Publ, 1992:2533-638.
  • 3 Bertolino PA, Freedberg IM. Disorders of epidermal appendages and related disorders. In: Freedberg IM, Eisen AZ, Wollf K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB (eds). Dermatology in general medicine, 4 ed. New York: Mc Graw-Hill Inc, 1993:679-80.
  • 4 Habif TP. Clinical dermatology. 2 ed. St. Louis: Mosby Company, 1990:598-614.
  • 5 Takashima I. Androgenetic alopecia: clinical pathophysiological aspects in man and animals. In: Orfanos CE (ed). Hair and Hair Diseases. Berlin: Springer-Verlag, 1990:467-81.
  • 6 Orfanos CE. Androgenetic alopecia: clinical aspects and treatment. In: Orfanos CE (ed). Hair and Hair Diseases. Berlin: Springer-Verlag, 1990:487-520.
  • 7 Olsen EA. Androgenetic alopecia. In: Olsen EA (ed). Disorders of hair growth: diagnosis and treatment. New York: Mc Graw-Hill Inc, 1993:257-83.
  • 8 Feinstein R. Androgenetic alopecia. In: Sperling L, Yoo E, Chan E, Quirk C, Elston D (eds). Online textbook of dermatology. Emedicine Ýnc, 2000.
  • 9 Sezgin S, Köþlü A. Androgenetik alopesi konsepti. Galenos 1999;3(29):3-7.
  • 10 Hamilton JB. Patterned long hair in man; types and incidences. Ann NY Acad Sci 1951;53:708-14.
  • 11 Ebling FJG, Dawber R, Rook A: The hair. In: Rook A, Wilkinson DS, Ebling FJG, Champion RH, Burton JL (eds). Textbook of dermatology, 4 ed. Oxford: Blackwell Scientific Publ, 1986;1937-2037.
  • 12 Norwood OTT. Male pattern baldness: classifacition and incidence. Southern Med J 1975;68:1359-65.
  • 13 Ludwig E. Classification of the androgenetic alopecia (common baldness) occuring in the females sex. Br J Dermatol 1977;97:247.
  • 14 Rook A, Dawber R. Diseases of the hair and scalp. Oxford: Blackwell Scientific Publ, 1982;90-114.
  • 15 Venning VA, Dawber RPR. Patterned androgenetic alopecia in women. J Am Acad Dermatol 1998;18:1073-7.
  • 16 Roberts LJ. Androgenetic alopecia in men and women: an overview of cause and treatment. Dermatol Nurs 1997;9(6):379-86.
  • 17 Olsen EA. Hair disorders. In: Freedberg IM, Eisen AZ, Wollf K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB (eds). Dermatology in general medicine, 5 ed. New York: Mc Graw-Hill Inc, 1999:739-740.
  • 18 Nakanishi J. Expression of androgen receptor, type I and type II 5-reductase in human dermal papilla cells. In: van Neste D, Randall VA (eds). Hair research for the next millennium. Amsterdam: Elsevier Sience, 1996:307-10.
  • 19 Russel DW. Expression of steroid 5-reductase I and II in scalp skin in normal controls and in androgenetic alopecia. In: van Neste D, Randall VA (eds). Hair research for the next millennium. Amsterdam: Elsevier Sience, 1996:339-40.
  • 20 Buhl AE. Effects of a topical type I 5-reductase inhibitor, LY-191704, on scalp hair growth and sebum in balding stumptail macaques. In: van Neste D, Randall VA (eds). Hair research for the next millennium. Amsterdam: Elsevier Sience, 1996:245-8.
  • 21 Rhodes L. Effects of 1 year treatment with oral MK386, an inhibitor of type I 5-reductase in the stumptailed macque (Macaca actoides). J Invest Dermatol 1995;104: 658.
  • 22 Diani AR, Mulholland MJ, Shull KL, Kubicek MF, Johnson GA, Schostarez HJ, Brunden MN, Buhl AE. Hair growth effects of oral administration of finasteride, a steroid 5-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque. J Clin Endocrinol Metab 1992;74:345-50.
  • 23 Sawaya ME, Price VH. Different levels of 5-reductase type I and II aromatase and androgen receptors in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997;10(3):296-300.
  • 24 Sawaya ME. Steroid chemistry and hormone controls during the hair follicle cycle. Ann NY Acad Sci 1991;642:376-83
  • 25 Sawaya ME, Honig LS, Garland LD, Hsia SL. Delta 53 beta-hydroxysteroid dehydrogenase activity in sebaceous glands of scalp in male-pattern baldness. J Invest Dermatol . 1988;91:101-5.
  • 26 Sawaya ME. Biochemical mechanisms regulating human hair growth. Skin Pharmacol 1994;7(1-2):5-7.
  • 27 Sawaya ME. Two forms of androgen receptor proteinin human hair follicles and sebaceous glands: variation in transitional and bald scalp. J Invest Dermatol 1988;90:606.
  • 28 Sinclair R. Male pattern androgenetic alopecia. BMJ 1998;317:865-9.
  • 29 Rushton DH, Ramsay ID, Norris MJ, Gilkes JJ. Natural progression of male pattern baldness in young men. Clin Exp Dermatol 1991;16:188-92.
  • 30 Soyuer Ü. Alopesilerde etyopatogenez. Taþpýnar A (ed.): IX. Prof. Dr. A. Lütfü Tat Simpozyumu Kitabý'nda. Ankara: Yargýçoðlu Matbaasý, 1990:48-52.
  • 31 Kligman AM. The comparative histopathology of male pattern baldness and senescent baldness. Clin Dermatol 1998;6:108-18.
  • 32 Whiting D. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol 1993;28:755-763.
  • 33 Sperling LC, Winton GB. The transverse anatomy of androgenetic alopecia. J Dermatol Surg Oncol 1990;16:1127-33.
  • 34 Unger W, Nordstom R. Hair Transplantation. 3 ed. New York: Marcel Dekker, 1995.
  • 35 Shupack J, Stiller M. Status of medical treatment for androgenetic alopecia. Int J Dermatol 1993; 32 (10) : 701-6.
  • 36 Olsen EA, Weiner MS, Delong Er, Pinnell S. Topical minoxidil in early male pattern baldness. J Am Acad Dermatol 1985;13:185-92.
  • 37 Roberts J. Androgenetic alopecia: Treatment with topcal minoxidil. J Am Acad Dermatol 1987; 16(3): 705-710.
  • 38 Peluso AM, Miscidi C, Vincenzi C, Tosti A. Diffuse hypertrichosis during treatment with 5% topical minoxidil. Br J Dermatol 1997;136:118-20.
  • 39 Price VH, Menefee E. Quantitative estimation of hair growth: Comparative changes in weight and hair count with 5% and 2% minoxidil, placebo and no treatment. In: van Neste D, Randall VA (eds). Hair Research for the Next Millenium. Amsterdam: Elsevier Science, 1996:67-71.
  • 40 Shaw JC. Antiandrogen therapy in dermatology. Int J Dermatol 1996;35(11):770-76.
  • 41 Chen W, Zouboulis CC, Orfanos CE. The 5 alphareductase system and its inhibitors. Recent development and its perspective in treating androgendependent skin disorders.Dermatology 1996;193:177- 84.
  • 42 Rittmaster RS. Finasterid. N Engl J Med 1994;13:120- 1.
  • 43 Amichia B, Grunwald MH, Sobel R. 5 alpha-reductase inhibitors: a new hope in dermatology. Int J Dermatol 1997;36:182-4.
  • 44 Dallob AL, Sadick NS, Unger W, Lipert S, Geissler LA, Gregoire SL et al. The effect of finasteride a 5 alphareductase inhibitor, on scalp skin testosterone and dihydrotetosterone concentrations in patients with male pattern baldness. J Clin End and Metab 1994;79:703-6.
  • 45 McClellan KJ, Markham A. Finasteride; a review of its use in male pattern hair loss. Drugs 1999;57(1):111-26.
  • 46 Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998;39:578-89.
  • 47 Cash TF. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol 1992;26:926-31.
  • 48 Cash TF, Price VH, Savin RC. Psychological effects of androgetic alopecia on women: comparisons with balding men and with female control subjects. J Am Acad Dermatol. 1993;29:568-75.

Androgenetic Alopecia

Year 2000, Volume: 1 Issue: 3, 39 - 46, 01.12.2000

Abstract

Androgenetic alopecia is an androgen-dependent hair loss of the scalp in genetically predisposed male and female patients. Nowadays hair shedding has an effect on life quality of the individuals and there is a need of various therapy modalities for hair loss in recent years. Although androgenetic alopecia is accepted as a physiological process, as it has a progressive course, predominantly this type of alopecia influences life style of the patients. In this report the etiopathogenesis, clinical features, the effects on quality of life and recent advances in therapy of androgenetic alopecia is reviewed with the relevant literature.

References

  • 1 Braun-Falco O, Plewig G, Wolff HH, Winkelmann RK. Dermatology. 4 ed. Berlin: Springer-Verlag, 1991:772-4.
  • 2 Dawber RPR, Ebling FJG, Wojnarowska FT. Disorders of hair. In: Champion RH, Burton JL, Ebling FJG (eds). Textbook of dermatology, 5 ed. Oxford: Blackwell Scientific Publ, 1992:2533-638.
  • 3 Bertolino PA, Freedberg IM. Disorders of epidermal appendages and related disorders. In: Freedberg IM, Eisen AZ, Wollf K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB (eds). Dermatology in general medicine, 4 ed. New York: Mc Graw-Hill Inc, 1993:679-80.
  • 4 Habif TP. Clinical dermatology. 2 ed. St. Louis: Mosby Company, 1990:598-614.
  • 5 Takashima I. Androgenetic alopecia: clinical pathophysiological aspects in man and animals. In: Orfanos CE (ed). Hair and Hair Diseases. Berlin: Springer-Verlag, 1990:467-81.
  • 6 Orfanos CE. Androgenetic alopecia: clinical aspects and treatment. In: Orfanos CE (ed). Hair and Hair Diseases. Berlin: Springer-Verlag, 1990:487-520.
  • 7 Olsen EA. Androgenetic alopecia. In: Olsen EA (ed). Disorders of hair growth: diagnosis and treatment. New York: Mc Graw-Hill Inc, 1993:257-83.
  • 8 Feinstein R. Androgenetic alopecia. In: Sperling L, Yoo E, Chan E, Quirk C, Elston D (eds). Online textbook of dermatology. Emedicine Ýnc, 2000.
  • 9 Sezgin S, Köþlü A. Androgenetik alopesi konsepti. Galenos 1999;3(29):3-7.
  • 10 Hamilton JB. Patterned long hair in man; types and incidences. Ann NY Acad Sci 1951;53:708-14.
  • 11 Ebling FJG, Dawber R, Rook A: The hair. In: Rook A, Wilkinson DS, Ebling FJG, Champion RH, Burton JL (eds). Textbook of dermatology, 4 ed. Oxford: Blackwell Scientific Publ, 1986;1937-2037.
  • 12 Norwood OTT. Male pattern baldness: classifacition and incidence. Southern Med J 1975;68:1359-65.
  • 13 Ludwig E. Classification of the androgenetic alopecia (common baldness) occuring in the females sex. Br J Dermatol 1977;97:247.
  • 14 Rook A, Dawber R. Diseases of the hair and scalp. Oxford: Blackwell Scientific Publ, 1982;90-114.
  • 15 Venning VA, Dawber RPR. Patterned androgenetic alopecia in women. J Am Acad Dermatol 1998;18:1073-7.
  • 16 Roberts LJ. Androgenetic alopecia in men and women: an overview of cause and treatment. Dermatol Nurs 1997;9(6):379-86.
  • 17 Olsen EA. Hair disorders. In: Freedberg IM, Eisen AZ, Wollf K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB (eds). Dermatology in general medicine, 5 ed. New York: Mc Graw-Hill Inc, 1999:739-740.
  • 18 Nakanishi J. Expression of androgen receptor, type I and type II 5-reductase in human dermal papilla cells. In: van Neste D, Randall VA (eds). Hair research for the next millennium. Amsterdam: Elsevier Sience, 1996:307-10.
  • 19 Russel DW. Expression of steroid 5-reductase I and II in scalp skin in normal controls and in androgenetic alopecia. In: van Neste D, Randall VA (eds). Hair research for the next millennium. Amsterdam: Elsevier Sience, 1996:339-40.
  • 20 Buhl AE. Effects of a topical type I 5-reductase inhibitor, LY-191704, on scalp hair growth and sebum in balding stumptail macaques. In: van Neste D, Randall VA (eds). Hair research for the next millennium. Amsterdam: Elsevier Sience, 1996:245-8.
  • 21 Rhodes L. Effects of 1 year treatment with oral MK386, an inhibitor of type I 5-reductase in the stumptailed macque (Macaca actoides). J Invest Dermatol 1995;104: 658.
  • 22 Diani AR, Mulholland MJ, Shull KL, Kubicek MF, Johnson GA, Schostarez HJ, Brunden MN, Buhl AE. Hair growth effects of oral administration of finasteride, a steroid 5-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque. J Clin Endocrinol Metab 1992;74:345-50.
  • 23 Sawaya ME, Price VH. Different levels of 5-reductase type I and II aromatase and androgen receptors in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997;10(3):296-300.
  • 24 Sawaya ME. Steroid chemistry and hormone controls during the hair follicle cycle. Ann NY Acad Sci 1991;642:376-83
  • 25 Sawaya ME, Honig LS, Garland LD, Hsia SL. Delta 53 beta-hydroxysteroid dehydrogenase activity in sebaceous glands of scalp in male-pattern baldness. J Invest Dermatol . 1988;91:101-5.
  • 26 Sawaya ME. Biochemical mechanisms regulating human hair growth. Skin Pharmacol 1994;7(1-2):5-7.
  • 27 Sawaya ME. Two forms of androgen receptor proteinin human hair follicles and sebaceous glands: variation in transitional and bald scalp. J Invest Dermatol 1988;90:606.
  • 28 Sinclair R. Male pattern androgenetic alopecia. BMJ 1998;317:865-9.
  • 29 Rushton DH, Ramsay ID, Norris MJ, Gilkes JJ. Natural progression of male pattern baldness in young men. Clin Exp Dermatol 1991;16:188-92.
  • 30 Soyuer Ü. Alopesilerde etyopatogenez. Taþpýnar A (ed.): IX. Prof. Dr. A. Lütfü Tat Simpozyumu Kitabý'nda. Ankara: Yargýçoðlu Matbaasý, 1990:48-52.
  • 31 Kligman AM. The comparative histopathology of male pattern baldness and senescent baldness. Clin Dermatol 1998;6:108-18.
  • 32 Whiting D. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol 1993;28:755-763.
  • 33 Sperling LC, Winton GB. The transverse anatomy of androgenetic alopecia. J Dermatol Surg Oncol 1990;16:1127-33.
  • 34 Unger W, Nordstom R. Hair Transplantation. 3 ed. New York: Marcel Dekker, 1995.
  • 35 Shupack J, Stiller M. Status of medical treatment for androgenetic alopecia. Int J Dermatol 1993; 32 (10) : 701-6.
  • 36 Olsen EA, Weiner MS, Delong Er, Pinnell S. Topical minoxidil in early male pattern baldness. J Am Acad Dermatol 1985;13:185-92.
  • 37 Roberts J. Androgenetic alopecia: Treatment with topcal minoxidil. J Am Acad Dermatol 1987; 16(3): 705-710.
  • 38 Peluso AM, Miscidi C, Vincenzi C, Tosti A. Diffuse hypertrichosis during treatment with 5% topical minoxidil. Br J Dermatol 1997;136:118-20.
  • 39 Price VH, Menefee E. Quantitative estimation of hair growth: Comparative changes in weight and hair count with 5% and 2% minoxidil, placebo and no treatment. In: van Neste D, Randall VA (eds). Hair Research for the Next Millenium. Amsterdam: Elsevier Science, 1996:67-71.
  • 40 Shaw JC. Antiandrogen therapy in dermatology. Int J Dermatol 1996;35(11):770-76.
  • 41 Chen W, Zouboulis CC, Orfanos CE. The 5 alphareductase system and its inhibitors. Recent development and its perspective in treating androgendependent skin disorders.Dermatology 1996;193:177- 84.
  • 42 Rittmaster RS. Finasterid. N Engl J Med 1994;13:120- 1.
  • 43 Amichia B, Grunwald MH, Sobel R. 5 alpha-reductase inhibitors: a new hope in dermatology. Int J Dermatol 1997;36:182-4.
  • 44 Dallob AL, Sadick NS, Unger W, Lipert S, Geissler LA, Gregoire SL et al. The effect of finasteride a 5 alphareductase inhibitor, on scalp skin testosterone and dihydrotetosterone concentrations in patients with male pattern baldness. J Clin End and Metab 1994;79:703-6.
  • 45 McClellan KJ, Markham A. Finasteride; a review of its use in male pattern hair loss. Drugs 1999;57(1):111-26.
  • 46 Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998;39:578-89.
  • 47 Cash TF. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol 1992;26:926-31.
  • 48 Cash TF, Price VH, Savin RC. Psychological effects of androgetic alopecia on women: comparisons with balding men and with female control subjects. J Am Acad Dermatol. 1993;29:568-75.
There are 48 citations in total.

Details

Other ID JA85JV88BN
Journal Section Research Article
Authors

Neslihan Şendur This is me

Göksun (can) Karaman This is me

Publication Date December 1, 2000
Published in Issue Year 2000 Volume: 1 Issue: 3

Cite

EndNote Şendur N, Karaman G( (December 1, 2000) Androgenetic Alopecia. Meandros Medical And Dental Journal 1 3 39–46.